Improving Treatment of Major Depressive Disorder by Reducing Negative Future-Oriented Mental Imagery
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Jun 6, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help people with Major Depressive Disorder (MDD) by targeting negative thoughts about the future. Many patients with MDD find that traditional treatments don’t work well for them, so researchers want to see if a technique called "imagery rescripting" can help. In this study, half of the 50 participants will receive standard treatment along with 3-5 sessions of imagery rescripting, where they will learn to change distressing future images, like thoughts of suicide or loss, into more positive ones. The other half will only receive the standard treatment.
To be eligible, participants must be at least 18 years old, diagnosed with MDD, and have specific negative thoughts that cause them distress. All participants will complete some questionnaires and a brief online or phone interview at the start of the study. After finishing the study, they will receive a €25 reimbursement. This pilot study aims to find out if this new approach is acceptable and feasible for patients, which will help in planning a larger study in the future to better understand its effectiveness. There are no major risks involved in participating, making it a safe option for those who qualify.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 18 years or older;
- • Meet DSM-5 criteria for major depressive disorder;
- • Presence of 1-3 negative future-oriented mental images, which cause distress;
- • Be able to understand questionnaires and study information letter;
- • In case of medication use: are stable on medication for six weeks or longer.
- Exclusion Criteria:
- • Current or history of psychotic disorder;
- • Current or history of bipolar disorder;
- • Severe cognitive impairment (e.g., mental retardation) as evidenced by educational records, parental report and/or clinical impression;
- • Current EMDR or imagery rescripting therapy;
- • Other circumstances that might affect participation (e.g., severe medical disorder, relocation).
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, Noord Holland, Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported